Mabel Mardones, MD
About Mabel Mardones, MD
Dr. Mabel Mardones is a board-certified medical oncologist and hematologist with an advanced sub-specialty expertise in breast cancer. She treats patients with all types of breast disease with cutting-edge treatments such as chemotherapy, immunotherapy, hormone therapy, and clinical trials. Dr. Mardones uses genomic testing for her patients to personalize therapies and practice precision/evidence-based medicine according to National Comprehensive Cancer Network (NCCN) guidelines.
She works closely with breast surgeons, radiation oncologists, plastic surgeons, and other sub-specialists and participates in a weekly breast tumor board conference. During these tumor boards, cancer experts collaborate and review cases, share knowledge, and determine the best possible treatment for each patient. Dr. Mardones develops customized treatment plans for each of her patients that incorporates cutting-edge therapies.
Clinical Care Expertise
Angiosarcoma of the Breast
Ductal Carcinoma in Situ (DCIS)
HER2+ Breast Cancers
High Risk Breast Cancer Prevention
Inflammatory Breast Cancer
Invasive Breast Cancer (IDC/ILC)
Lobular Carcinoma in Situ (LCIS)
Male Breast Cancer
Metastatic Breast Cancer
Paget Disease of the Breast
Pregnancy Associated Breast Cancer
Triple-Negative Breast Cancer
Young Women with Breast Cancer
Hematology & Oncology, Baylor University Hospital, Dallas, TX
Internal Medicine, University of Utah Clinics and Hospitals, Salt Lake City, UT
Loma Linda University School of Medicine, Loma Linda, CA
Patient Care Philosophy
I’m passionate about providing compassionate, patient-centered care to women with breast cancer with a special focus on young women. I pride myself in being an educator and an advocate for my patients. I believe that at the center of excellent cancer care, is the understanding that patients are more than a diagnosis but rather a whole person. I believe that the therapies and treatments of the future are essential for my patients to have access to today. This is why I’m proud to be a leader in advancing cancer care through clinical research.
American Society of Clinical Oncology